POINT Biopharma Global Inc.

The surge of interest in radiopharmaceuticals for both diagnostics and therapeutics is likely to prove very beneficial for Germany’s PentixaPharm GmbH which has a promising treatment for CNS lymphom

South Korea's SK Biopharmaceuticals Co., Ltd is looking to continue its growth story via a new diversification into the globally hot area of radiopharmaceuticals through a licensing agreement with C

Radionetics Oncology , a three-year-old start-up that has raised $82.5m to date, landed a sweet deal with Eli Lilly and Company , with the big pharma paying $140m up front for an exclusive right to b

Big pharma’s march to shore up expertise in the budding area of radiopharmaceuticals continues, with Eli Lilly and Company announcing yet another deal in the field on 21 May. This time the company is